Company Overview of Trius Therapeutics, Inc.
Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for serious infections. It develops tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections; and completed phase 1 clinical trial for the treatment of pneumonia. The tedizolid phosphate is a novel antibiotic for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. The company also develops GyrB/ParE, which are under preclinical program and are targets of the fluoroquinolone class of antibacterial agents, such...
6310 Nancy Ridge Drive
San Diego, CA 92121
Founded in 2004
Key Executives for Trius Therapeutics, Inc.
Chief Executive Officer, President and Executive Director
Founder and Chief Scientific Officer
Founder and Director of Drug Discovery
Compensation as of Fiscal Year 2015.
Trius Therapeutics, Inc. Key Developments
Trius Therapeutics Wins $19,758,137 Federal Contract
Sep 24 13
Trius Therapeutics, San Diego, won a $19,758,137 federal contract from the U.S. Department of Health and Human Services' National Institutes of Health, Bethesda, Md., for the development of therapeutic medical countermeasures for biodefense and emerging infectious diseases.
Trius Therapeutics, Inc.(NasdaqGM:TSRX) dropped from Russell 2000 Index
Sep 12 13
Trius Therapeutics, Inc. will be removed from Russell 2000 Index.
Trius Therapeutics, Inc.(NasdaqGM:TSRX) dropped from Russell 3000 Index
Sep 12 13
Trius Therapeutics, Inc. will be removed from Russell 3000 Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries